Skip to main content
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
// //

Eli Lilly and Company NYSE: LLY-N

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

Today's Trading

Day Low 228.23
Day High 230.83
Open:229.71
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Fundamentals

Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Strong Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Turner Syndrome Market: by Industry Type, Growth, Share, Size, Key Manufacturers, Revenue, Trends, Growth, Geographical Outlook and Forecast to 2028
- AmericaNewsHour - Fri Sep 17, 9:40AM CDT
AmericaNewsHour - CMTX
Fri Sep 17, 9:40AM CDT
Research Nester published a report titled ": Global Demand Analysis & Opportunity Outlook 2028"which delivers a detailed overview of the turner syndrome drug market in terms of market segmentation by type, drug type, therapy type and by end-user.
Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19
- PR Newswire - PRF - Thu Sep 16, 2:57PM CDT
PR Newswire - PRF - CMTX
Thu Sep 16, 2:57PM CDT
/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis (PEP) in certain individuals for the prevention of SARS-CoV-2 infection, Eli Lilly and Company (NYSE: LLY) announced today. The neutralizing antibodies can now be used together to treat high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination, and have been exposed to someone infected with SARS-CoV-2 or who are at high risk of exposure in an institutional setting, including a nursing home or prison. This authorization follows the national reopening of distribution .
Neuroblastoma Drugs Market By Delivery, Type, Systems, End-User 2028
- AmericaNewsHour - Thu Sep 16, 8:33AM CDT
AmericaNewsHour - CMTX
Thu Sep 16, 8:33AM CDT
Research Nester published a report titled "- Global Demand Analysis and Opportunity Outlook 2020-2028" which delivers detailed overview of the neuroblastoma drugs market in terms of market segmentation by drug type, by mechanism type, by treatment type, by diagnosis type, by end users and by region.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 228.23 +0.82% increase
on 09/17/21
Period Open:272.71
Price movement based on the high, low and last over the given period.
274.76 -16.25% decrease
on 08/18/21
-42.61 (-15.62%) decrease
since 08/17/21
3-Month 217.00 +6.04% increase
on 06/23/21
Period Open:222.21
Price movement based on the high, low and last over the given period.
275.87 -16.59% decrease
on 08/17/21
+7.89 (+3.55%) increase
since 06/17/21
52-Week 129.21 +78.08% increase
on 10/30/20
Period Open:152.47
Price movement based on the high, low and last over the given period.
275.87 -16.59% decrease
on 08/17/21
+77.63 (+50.91%) increase
since 09/17/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies